Ongoing Study:

Phase 1b/2 Study of Annamycin in STS Lung Mets in the United States

Multi-Center, Open-Label, Single-Arm Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) With Pulmonary Metastases

Promising Early Clinical Activity in Phase 1b/2

Study Highlights:

Enrolling: ~18 Subjects in 1b portion

Treatment period: Single dose every 21 days

Does Escalation: From 210 mg to a max of 450 mg (currently enrolling 390 mg)

Primary Endpoint: Establish MTD/RP2D and safety

Planned Phase 2 expansion (25 patients) will evaluate efficacy

For complete study details, please view the study listing on Identifier: NCT04887298

Our Pipeline


Sign Up For Alerts